Candel Therapeutics Inc (NASDAQ: CADL) is 40.67% higher on its value in year-to-date trading and has touched a low of $1.34 and a high of $14.60 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CADL stock was last observed hovering at around $10.47 in the last trading session, with the day’s gains setting it 1.74%.
Currently trading at $12.21, the stock is 49.97% and 54.32% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.06 million and changing 16.62% at the moment leaves the stock 77.19% off its SMA200. CADL registered 609.88% gain for a year compared to 6-month gain of 132.57%.
The stock witnessed a 84.86% loss in the last 1 month and extending the period to 3 months gives it a 221.32%, and is 42.81% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.35% over the week and 8.00% over the month.
Candel Therapeutics Inc (CADL) has around 42 employees, a market worth around $543.05M and $0.00M in sales. Distance from 52-week low is 811.19% and -16.37% from its 52-week high.
The EPS is expected to shrink by -4.53% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
The shares outstanding are 32.13M, and float is at 30.51M with Short Float at 8.66%.
The top institutional shareholder in the company is NORTHPOND VENTURES, LLC with over 1.94 million shares valued at $12.0 million. The investor’s holdings represent 6.477 of the CADL Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 0.82 million shares valued at $5.1 million to account for 2.819 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 0.82 million shares representing 2.8035 and valued at over $5.08 million, while STATE STREET CORP holds 1.5824 of the shares totaling 0.47 million with a market value of $2.93 million.
Candel Therapeutics Inc (CADL) Insider Activity
The most recent transaction is an insider sale by Barone Francesca, the company’s Chief Scientific Officer. SEC filings show that Barone Francesca sold 13,534 shares of the company’s common stock on Jan 15 ’25 at a price of $7.22 per share for a total of $97783.0. Following the sale, the insider now owns 0.11 million shares.
Candel Therapeutics Inc disclosed in a document filed with the SEC on Jan 15 ’25 that Tyagarajan Seshu (Chief Technology Officer) sold a total of 14,322 shares of the company’s common stock. The trade occurred on Jan 15 ’25 and was made at $7.22 per share for $0.1 million. Following the transaction, the insider now directly holds 96790.0 shares of the CADL stock.
Still, SEC filings show that on Jan 15 ’25, Schoch Charles disposed off 9,511 shares at an average price of $7.22 for $68717.0. The insider now directly holds 43,038 shares of Candel Therapeutics Inc (CADL).
